53O Results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma
Year: 2024
Type: article
Study design: Clinical Trial
Abstract: AXL is a cell-surface receptor tyrosine kinase highly expressed in several sarcoma subtypes that has been associated with tumor resistance to chemotherapy. Mecbotamab vedotin (BA3011) is a conditionally active biologic anti-AXL antibody-drug conjugate (CAB-AXL-ADC) that conditionally and reversibly binds AXL under tumor-specific, low-pH conditions, which reduces off-tumor toxicity and immunogenicity, avoids tissue-mediated drug deposition, and improves pharmacokinetics.
Source: ESMO Open
Institutions: Northwestern University, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, Froedtert Hospital, Medical College of Wisconsin, Oregon Health & Science University, Huntsman Cancer Institute, Moffitt Cancer Center, University of Washington, Fred Hutch Cancer Center, Norton Healthcare, HealthONE, University of California, San Francisco, University of Hong Kong, Children's National, Chinese University of Hong Kong, Prince of Wales Hospital, Dana-Farber Cancer Institute, Nationwide Children's Hospital, The Ohio State University, University of Southern California, Children's Hospital of Los Angeles, Massachusetts General Hospital, University of Colorado Anschutz
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,730
OpenAlex ID: W4392880587